openPR Logo
Press release

Investigation announced for Long-Term Investors in NASDAQ: ACRS shares over possible Wrongdoing at Aclaris Therapeutics, Inc.

12-02-2019 06:52 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares.

An investigation on behalf of current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares.

An investigation was announced for long-term investors in shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) concerning potential breaches of fiduciary duties by certain directors of Aclaris Therapeutics, Inc..

Investors who are current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: ACRS stocks follows a lawsuit filed against Aclaris Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ACRS stocks, concerns whether certain Aclaris Therapeutics, directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the Defendants failed to disclose to investors that the Company’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales, that, as a result, the Company was reasonably likely to face regulatory scrutiny, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in NASDAQ: ACRS shares over possible Wrongdoing at Aclaris Therapeutics, Inc. here

News-ID: 1874796 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Aclaris

Vitiligo Drugs Market in 2025 Detailed Study Analysis | Dermavant Sciences, Inc. …
Coherent Market Insights announces the release of a market assessment report on the Vitiligo Drugs Market. The report Provides comprehensive and accurate research study on the market. It provides an in-depth analysis of key elements within the healthcare market, including market dynamics, competitive landscape, regional developments, and detailed segmentation across various healthcare services, products, and technologies. It provides verified market figures such as CAGR, SWOT Analysis, market share, revenue, volume,
Androgenetic Alopecia Treatment Market Future Business Opportunities 2025-2032 | …
Latest Report, titled "Androgenetic Alopecia Treatment Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Androgenetic Alopecia Treatment market has been
Hair Loss Treatment Market Is Booming Worldwide 2024-2031 | Viviscal, Cipla Inc. …
Global Hair Loss Treatment Market is estimated to be valued at US$ 4.24 Billion in 2023, and is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030). This report on the Hair Loss Treatment market offers an comprehensive analysis of the current trends, market size, and projections up to 2031. Combining qualitative and quantitative insights, the report covers key trends, challenges, opportunities, market size, growth forecasts, and recent
Cryopyrin-associated Periodic Syndrome Market Outlook Report 2032 | Zydus Cadila …
DelveInsight's "Cryopyrin-associated Periodic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Cryopyrin-associated Periodic Syndrome , historical and forecasted epidemiology as well as the Cryopyrin-associated Periodic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Cryopyrin-associated Periodic Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted
Computational Toxicology Technology Market Trends, Growth, Share, Size, Opportun …
The Computational Toxicology Technology worldwide market has been extensively examined in this study, highlighting crucial elements such as market rivalry, worldwide and regional expansion, market division, and market arrangement. The analysts responsible for the report have utilized cutting-edge research methods to gauge the value-based dimensions of the global market. Additionally, the report provides approximations for market portion, earnings, output, consumption, gross profit margin, CAGR, and other essential variables. Readers can
Androgenetic Alopecia Treatment Market Important Takeaways from Growth Perspecti …
The Androgenetic Alopecia Treatment Market Report examines many facets of the industry including market size, market status, market trends, and forecasts. The report also provides brief information on specific growth opportunities by competitors and key market drivers. The Market Report provides In-depth analysis of the market status of the Androgenetic Alopecia Treatment Top manufacturers with the best facts and figures, meaning, Definition, SWOT analysis, PESTLE analysis, expert opinions, and the